Myopia Pipeline 2025: Comprehensive Insights into Emerging Therapies, Clinical Developments, and Future Market Opportunities | DelveInsight

DelveInsight's "Myopia Pipeline Insight 2025" report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in the Myopia pipeline landscape. It covers the Myopia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myopia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Myopia Pipeline? Click here to explore the therapies and trials making headlines @ Myopia Pipeline Outlook Report [https://www.delveinsight.com/sample-request/myopia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Myopia Pipeline Report

* On 24 September 2025, Hoffmann-La Roche announced a Phase III, multicenter, randomized, double-masked, active comparator-controlled study evaluating the efficacy and safety of faricimab in patients with myopic choroidal neovascularization (CNV). This non-inferiority study will compare 6.0 mg faricimab versus 0.5 mg ranibizumab administered at a pro-re-nata (PRN) dosing regimen after an initial active IVT treatment administration at randomization (Day 1).
* DelveInsight's Myopia Pipeline report depicts a robust space with 8+ active players working to develop 10+ pipeline therapies for Myopia treatment.
* The leading Myopia Companies, such as Cloudbreak Pharma, Sunhawk Vision Biotech, Inc., iVeena Delivery Systems, Inc., Stuart Therapeutics and others.
* Promising Myopia Therapies such as SYD-101 Dose 1, Atropine sulfate eye drops 0.01%, Alleance Registered , Atropine Sulfate, Optifree Replenish, SHJ002, Atropine, Ranibizumab and others.

Want to know which companies are leading innovation in Myopia? Dive into the full pipeline insights @ Myopia Clinical Trials Assessment [https://www.delveinsight.com/sample-request/myopia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Myopia Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Myopia Pipeline Report also highlights the unmet needs with respect to the Myopia.

Myopia Overview

Myopia, also known as nearsightedness, is a common vision condition in which distant objects appear blurry while close objects can be seen clearly. It occurs when the eye grows too long from front to back or when the cornea is too curved, causing light rays to focus in front of the retina instead of directly on it. Myopia often begins in childhood and tends to progress into the teenage years, especially in cases where there is a strong genetic predisposition or environmental factors such as prolonged near work and limited outdoor activity.

Myopia Emerging Drugs Profile

* CBT-009: Cloudbreak Pharma

Atropine is a mydriatic agent, which clinically shows promising potential in treating progressive Myopia. Topical ophthalmic atropine sulfate has an extensive clinical history dating back several decades. Topical ophthalmic solution of 1% atropine sulfate has been approved worldwide for use in producing cycloplegia, mydriasis and in penalizing the healthy eye in treatment of amblyopia. CBT-009 is a novel ophthalmic formulation of atropine, which will substantially improve atropine stability in the formulation and ultimately product shelf life. Currently, the drug is in Phase III stage of its development for the treatment of Myopia.

* SHJ002: Sunhawk Vision Biotech, Inc.

SHJ002 is an investigational therapeutic being developed for the treatment of myopia, aimed at controlling the progression of axial elongation-a primary factor contributing to the condition. Designed as a topical formulation, SHJ002 targets key molecular pathways involved in scleral remodeling, potentially stabilizing the structural integrity of the eye. By addressing the biomechanical and biochemical changes that lead to myopic progression, SHJ002 offers a non-invasive approach with the potential to complement or enhance existing myopia management strategies such as optical correction and lifestyle modifications. Currently, the drug is in Phase II stage of its development for the treatment of Myopia.

* IVMED 85: iVeena Delivery Systems, Inc.

IVMED-85 is a daily eye drop that strengthens scleral and corneal collagen crosslinks through LOX activation, potentially leading to improved refraction and a decrease in the rate of axial elongation. It works by enhancing the activity of lysyl oxidase (LOX), an enzyme critical for stabilizing extracellular matrix proteins like collagen and elastin. This biochemical reinforcement increases the biomechanical strength of ocular tissues, reducing progressive deformation of the eye. By targeting the structural integrity of the sclera, IVMED-85 aims to slow or halt myopic progression at its root cause. Currently, the drug is in Phase I/II clinical studies for the treatment of Myopia.

If you're tracking ongoing Myopia Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Myopia Treatment Drugs [https://www.delveinsight.com/sample-request/myopia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Myopia Pipeline report provides insights into:-

* The report provides detailed insights about companies that are developing therapies for the treatment of Myopia with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myopia Treatment.
* Myopia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Myopia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Myopia market.

Myopia Companies

Cloudbreak Pharma, Sunhawk Vision Biotech, Inc., iVeena Delivery Systems, Inc., Stuart Therapeutics and others.

Myopia Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

Myopia Products have been categorized under various Molecule types such as

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

From emerging drug candidates to competitive intelligence, the Myopia Pipeline Report covers it all - check it out now @ Myopia Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/myopia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Myopia Pipeline Report

* Coverage- Global
* Myopia Companies- Cloudbreak Pharma, Sunhawk Vision Biotech, Inc., iVeena Delivery Systems, Inc., Stuart Therapeutics and others.
* Myopia Therapies- SYD-101 Dose 1, Atropine sulfate eye drops 0.01%, Alleance Registered , Atropine Sulfate, Optifree Replenish, SHJ002, Atropine, Ranibizumab and others.
* Myopia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Myopia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research - discover what's next for the Myopia Treatment landscape in this detailed analysis @ Myopia Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/myopia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Myopia: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Myopia- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* CBT-009: Cloudbreak Pharma
* Mid Stage Products (Phase II)
* SHJ002: Sunhawk Vision Biotech, Inc.
* Early Stage Products (Phase I/II)
* IVMED 85: iVeena Delivery Systems, Inc.
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Inactive Products
* Myopia Key Companies
* Myopia Key Products
* Myopia- Unmet Needs
* Myopia- Market Drivers and Barriers
* Myopia- Future Perspectives and Conclusion
* Myopia Analyst Views
* Myopia Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=myopia-pipeline-2025-comprehensive-insights-into-emerging-therapies-clinical-developments-and-future-market-opportunities-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/myopia-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.